Pages that link to "Q44558806"

The following pages link to The combination of yondelis and cisplatin is synergistic against human tumor xenografts (Q44558806):

Displaying 33 items.

• Trabectedin and its potential in the treatment of soft tissue sarcoma. (Q33380903) (← links)
• Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. (Q33921802) (← links)
• Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. (Q34616904) (← links)
• Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma (Q34622323) (← links)
• Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models (Q34898364) (← links)
• Oncolytic virotherapy for ovarian cancer (Q35597082) (← links)
• Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma (Q36230812) (← links)
• Sarcomas and pharmacogenetics (Q36249224) (← links)
• A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer (Q36614276) (← links)
• The current treatment of recurrent ovarian cancer (Q36623372) (← links)
• Ovarian cancer: a focus on management of recurrent disease (Q36642130) (← links)
• Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. (Q36967173) (← links)
• Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives (Q37760957) (← links)
• Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer (Q37765581) (← links)
• New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer (Q37809986) (← links)
• Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics (Q38255906) (← links)
• Unique features of trabectedin mechanism of action. (Q38669051) (← links)
• The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. (Q38797843) (← links)
• Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. (Q39497253) (← links)
• Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells (Q39534106) (← links)
• The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models. (Q39557188) (← links)
• The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo (Q41851530) (← links)
• Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells (Q42108466) (← links)
• Rationale for drug combinations (Q44558797) (← links)
• Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. (Q45916912) (← links)
• Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest (Q47107250) (← links)
• Trabectedin has promising antineoplastic activity in high-grade meningioma (Q48627774) (← links)
• New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials†. (Q55712396) (← links)
• EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group (Q60589806) (← links)
• Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors (Q62944906) (← links)
• Mechanisms of drug combinations: interaction and network perspectives (Q83265745) (← links)
• Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors (Q85169133) (← links)
• Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer (Q90183658) (← links)